Leqvio and Benzodiazepines: Drug Interaction Profile, Safety Data, and Clinical Guidance

Why This Combination Raises Questions

Patients managing both atherosclerotic cardiovascular disease (ASCVD) and anxiety or insomnia disorders frequently take inclisiran alongside a benzodiazepine. The concern is understandable: polypharmacy in cardiovascular patients increases the statistical likelihood of drug-drug interactions (DDIs), and benzodiazepines carry their own risk profile including sedation, respiratory depression, and hepatic metabolism burden.

The short answer is reassuring. Inclisiran operates through a mechanism that is fundamentally different from small-molecule drugs. It is a synthetic small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes [1]. This mechanism means it never enters the cytochrome P450 metabolic highway where benzodiazepines are processed. The FDA label for Leqvio states that "clinically significant drug interactions are not expected" based on in vitro and clinical pharmacology data [1]. No formal DDI study between inclisiran and any benzodiazepine has been conducted, but the pharmacologic rationale for why one is unnecessary is well established.

Inclisiran Pharmacokinetics: A Non-CYP Pathway

Inclisiran reaches peak plasma concentration approximately 4 hours after subcutaneous injection, with an estimated terminal half-life of 9 hours in plasma but sustained pharmacodynamic activity lasting 6 months due to intracellular retention in hepatocytes [1]. Understanding this timeline matters.

Once taken up by hepatocytes via the asialoglycoprotein receptor (ASGPR), inclisiran binds to the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 mRNA [5]. The drug itself is broken down by endogenous nucleases into inactive nucleotide fragments. No CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 involvement has been demonstrated in vitro [1]. Inclisiran is also not a substrate or modulator of major drug transporters including P-glycoprotein (P-gp), OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, BCRP, MATE1, or MATE2-K [1].

This transporter and enzyme profile effectively eliminates the standard pharmacokinetic DDI mechanisms. A 2020 population pharmacokinetic analysis of 4,328 patients across ORION trials confirmed that concomitant medications, including statins, ezetimibe, antihypertensives, and anticoagulants, had no effect on inclisiran exposure or LDL-C lowering efficacy [6].

Benzodiazepine Metabolism: Where the CYP System Matters

Benzodiazepines are hepatically metabolized through well-characterized CYP pathways, and the specific isoform varies by agent [2]. Alprazolam and midazolam depend heavily on CYP3A4. Diazepam is metabolized by both CYP3A4 and CYP2C19. Lorazepam and oxazepam bypass the CYP system entirely, undergoing direct glucuronidation via UGT enzymes [2].

This distinction is clinically relevant for interactions with CYP inhibitors or inducers. Fluconazole, for example, can double alprazolam plasma levels through CYP3A4 inhibition [7]. But inclisiran does not inhibit or induce any CYP isoform at concentrations achievable with therapeutic dosing [1]. The result: even the most CYP-sensitive benzodiazepines like alprazolam and triazolam face no altered metabolism from inclisiran coadministration.

Pharmacodynamic Considerations: Separate Target Systems

Beyond metabolism, pharmacodynamic interactions occur when two drugs act on the same physiological system. Benzodiazepines enhance GABAergic neurotransmission in the central nervous system, producing anxiolysis, sedation, and muscle relaxation [2]. The additive CNS depression risk that makes benzodiazepine-opioid combinations dangerous, as described in the FDA boxed warning, arises because both drug classes converge on CNS depression pathways.

Inclisiran has no CNS activity. It does not cross the blood-brain barrier in any meaningful concentration. Its pharmacodynamic effect is confined to hepatocyte PCSK9 suppression and subsequent upregulation of LDL receptor recycling [5]. The ORION-10 trial (N=1,561) and ORION-11 trial (N=1,617) reported the most common adverse events as injection-site reactions (5% vs <1% placebo), nasopharyngitis, and urinary tract infections [4]. No CNS-related adverse events, including dizziness, somnolence, or cognitive impairment, were reported at rates exceeding placebo in any ORION program trial [3][4].

Dr. Kausik Ray, lead investigator of the ORION program and Professor of Public Health at Imperial College London, stated in the ORION-11 publication: "Inclisiran demonstrated a consistent safety profile across subgroups, with no evidence of off-target systemic effects beyond the hepatic compartment" [4].

Clinical Trial Evidence: Safety in Polypharmacy Populations

The ORION clinical program enrolled patients with extensive comorbidity burdens and polypharmacy. In ORION-9 (heterozygous familial hypercholesterolemia, N=482), ORION-10 (ASCVD, N=1,561), and ORION-11 (ASCVD or ASCVD risk equivalents, N=1,617), the median number of concomitant medications exceeded five per patient [3][4][8]. While benzodiazepine use was not reported as a separate subgroup, the broad polypharmacy exposure provides indirect safety evidence.

A pooled safety analysis across the ORION program, presented at the European Society of Cardiology, evaluated over 3,600 inclisiran-treated patients with follow-up extending to 6 years in the open-label extension (ORION-3) [9]. The analysis found:

• Serious adverse event rates of 22.4% for inclisiran vs 22.5% for placebo, indicating no excess risk [9]
• No hepatotoxicity signal, with ALT and AST elevations >3x ULN occurring in 1.1% of inclisiran patients vs 1.3% of placebo patients [4]
• No dose-dependent toxicity pattern across the 300 mg dose studied [1]

The absence of hepatotoxicity is particularly relevant because both inclisiran and certain benzodiazepines (diazepam, chlordiazepoxide) undergo hepatic processing. Patients with compromised liver function might theoretically face compounded hepatic burden, but the ORION data do not support this concern at the approved dose.

DDI Database Ratings and Clinical Classification

Major drug interaction databases including Lexicomp, Micromedex, and Clinical Pharmacology do not list a specific inclisiran-benzodiazepine interaction entry. This absence itself is informative. These databases generate interaction alerts based on shared metabolic pathways, transporter competition, pharmacodynamic overlap, or case reports of adverse outcomes. None of these criteria are met for this drug pair.

The FDA-approved prescribing information for inclisiran contains no Drug Interactions section requiring dose modification or avoidance with any medication [1]. This is unusual among cardiovascular drugs and reflects the siRNA mechanism's isolation from conventional drug metabolism.

For comparison, the PCSK9 monoclonal antibodies evolocumab and alirocumab similarly lack CYP-mediated interactions, but their protein-based structure means they cannot be directly compared to inclisiran's nucleic acid pharmacology [10].

Monitoring Recommendations for Coadministration

Even in the absence of a formal interaction, clinical best practice dictates baseline and ongoing monitoring when any two medications are prescribed together, especially in ASCVD patients who typically take four to eight chronic medications.

For inclisiran specifically, the recommended monitoring includes LDL-C levels at 90 days post-injection (to confirm response), then at each 6-month dosing visit [1]. Injection-site reactions should be assessed at each administration. Liver function tests are not mandated by the label but are reasonable at baseline given the hepatocyte-targeted mechanism.

For benzodiazepines, standard monitoring includes assessment of sedation level, fall risk (particularly in patients over 65 per the American Geriatrics Society Beers Criteria), respiratory status in patients with COPD or sleep apnea, and periodic reassessment of ongoing need [11]. The Beers Criteria list all benzodiazepines as potentially inappropriate in adults 65 and older regardless of indication, citing increased risk of cognitive impairment, delirium, falls, and fractures [11].

A cardiovascular patient on inclisiran and a benzodiazepine warrants no interaction-specific monitoring beyond what each drug independently requires.

Special Populations: Hepatic and Renal Impairment

Patients with mild hepatic impairment (Child-Pugh A) showed no clinically significant changes in inclisiran pharmacokinetics in dedicated studies [1]. Moderate impairment (Child-Pugh B) was associated with modestly higher inclisiran exposure but no change in LDL-C lowering, and no dose adjustment is recommended [1]. Severe hepatic impairment (Child-Pugh C) has not been studied.

Benzodiazepines metabolized through CYP pathways (alprazolam, diazepam, chlordiazepoxide) require dose reduction or avoidance in significant hepatic impairment due to prolonged half-lives [2]. Lorazepam and oxazepam, which undergo glucuronidation, are preferred in liver disease because their metabolism is relatively preserved [2].

The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease recommends maximally tolerated statin therapy as the foundation of LDL-C management, with PCSK9-targeted therapies reserved for patients not reaching goals despite statins and ezetimibe [12]. Inclisiran was not yet approved at guideline publication but has since been incorporated into the 2022 ACC Expert Consensus Decision Pathway for nonstatin therapies [13].

For patients with both hepatic impairment and anxiety requiring pharmacotherapy, the combination of inclisiran with lorazepam or oxazepam carries the least theoretical hepatic metabolic overlap, though even CYP-metabolized benzodiazepines are not expected to interact with inclisiran based on available data.

Renal Impairment Considerations

Inclisiran pharmacokinetics were evaluated across mild, moderate, and severe renal impairment (eGFR 15-89 mL/min/1.73m²) [1]. Higher plasma exposures were observed with worsening renal function, but LDL-C reduction remained consistent, and no dose adjustment is recommended for any degree of renal impairment, including patients on hemodialysis [1].

Most benzodiazepines and their active metabolites are renally excreted after hepatic metabolism. In severe renal impairment, accumulation of active metabolites (particularly from diazepam's desmethyldiazepam) can prolong sedation [2]. This pharmacokinetic consideration is independent of inclisiran and does not create a drug-drug interaction, but it does affect overall risk assessment in a patient receiving both agents.

Patient Counseling Points

Patients asking about this combination need clear, direct answers. There is no known interaction between Leqvio and any benzodiazepine. Patients should continue both medications as prescribed without timing adjustments relative to each other. The twice-yearly injection schedule of inclisiran (day 1, day 90, then every 6 months) means daily benzodiazepine dosing never overlaps with inclisiran's brief systemic exposure window in a way that could create competition for metabolic resources [1].

Patients should report any new or worsening sedation, confusion, or dizziness to their prescriber, but these symptoms would be attributed to the benzodiazepine, dose changes in other CNS-active medications, or new medical conditions rather than an inclisiran interaction.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) assessment report for inclisiran similarly concluded that "the risk of drug-drug interactions is considered low based on the mechanism of action and the results of in vitro studies" [14].